Showing results (231-240 of 6,879) with videos related to
Sort By:
Pageof 688
Leukemia Research|January 1, 1987
Serial measurements of beta-2-microglobulin in plasma correlates with white blood cell counts and haptocorrin in chronic myeloid leukemiaO W Bjerrum, P GimsingLeukemia Research|January 1, 1988
Induction of proliferation of acute myeloblastic leukemia (AML) cells with hemopoietic growth factorsP Lista, M F Brizzi, G Avanzi, et al.Leukemia Research|March 9, 2020
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemiaElizabeth A Griffiths, Hetty E Carraway, Namrata S Chandhok, et al.Leukemia Research|January 1, 1988
Effect of cobalamin inactivation on folate metabolism of leukemic cellsA A Ermens, A C Kroes, M Schoester, et al.Leukemia Research|January 22, 2019
A registry-based analysis of survival outcomes in mast cell leukemiaJustin Budnik, Michael T MilanoLeukemia Research|January 7, 2019
Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on ironStaci L Haney, Michelle L Varney, Hannah R Safranek, et al.Leukemia Research|December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆Karen Yee, Cristina Papayannidis, Norbert Vey, et al.Leukemia Research|December 4, 2018
Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemiaKi-Hoon Kang, Soo-Hyun Kim, Soo-Young Choi, et al.Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.Leukemia Research|December 31, 2013
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitorSrdan Verstovsek, Constantine S Tam, Martha Wadleigh, et al.Pageof 688